153993-99-8

Basic information

• Product Name: 2-Pyridinecarbonitrile,4-(bromomethyl)-(9CI)
• Synonyms: 2-Pyridinecarbonitrile,4-(bromomethyl)-(9CI);4-(BroMoMethyl)picolinonitrile;4-Bromomethyl-pyridine-2-carbonitrile
• CAS NO: 153993-99-8
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.032
• Product Categories: PYRIDINE
• Mol File: 153993-99-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-Pyridinecarbonitrile,4-(bromomethyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarbonitrile,4-(bromomethyl)-(9CI)(153993-99-8)
• EPA Substance Registry System: 2-Pyridinecarbonitrile,4-(bromomethyl)-(9CI)(153993-99-8)

Safety Data

• Hazardous Substances Data: 153993-99-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyridinecarbonitrile,4-(bromomethyl)-(9CI) is used as a building block for the synthesis of various pharmaceutical compounds. Its unique chemical properties, including the presence of the bromomethyl group, make it a valuable component in the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Pyridinecarbonitrile,4-(bromomethyl)-(9CI) is utilized as a building block for the synthesis of various agrochemical compounds. Its potential applications in this field may include the development of new pesticides or other agrochemical products.
Used in Organic Synthesis:
2-Pyridinecarbonitrile,4-(bromomethyl)-(9CI) is used as a reagent in organic synthesis to introduce the cyano group into organic molecules. This property makes it a useful tool in the synthesis of a wide range of organic compounds.
Safety Considerations:
Due to its potentially hazardous nature, 2-Pyridinecarbonitrile,4-(bromomethyl)-(9CI) should be handled with care and in accordance with proper safety protocols. This includes the use of appropriate personal protective equipment and adherence to established safety guidelines to minimize risks associated with its use.

Upstream product

• 1620-76-4 2-Cyano-4-methylpyridin 
• 22346-75-4 4-pyridylcarbinol-N-oxide 
• 71935-32-5 2-Cyano-4-(hydroxymethyl)pyridine 
• 603-35-0 triphenylphosphine 
• 1003-67-4 4-methylpyridine-1-oxide 
• 117423-43-5 2-cyano-4-[{(tert-butyldimethylsilyl)oxy}methyl]pyridine 

Downstream Products

• 858362-83-1 4-(aminomethyl)pyridine-2-carbonitrile 

Relevant articles and documents

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint

Immune checkpoint blockade is one of the most promising strategies of cancer immunotherapy. However, unlike classical targeted therapies, it is currently solely based on expensive monoclonal antibodies, which often inflict immune-related adverse events. H

MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFECTIVE VACCINE ADJUVANT

Disclosed are inhibitors of mevalonate pathway as an efficient vaccine adjuvant and use thereof. In particular, the inhibitor is an acetoacetyl-CoA transferase inhibitor, a HMG-CoA synthase inhibitor, a HMG-CoA reductase inhibitor, a mevalonate kinase inhibitor, a phosphomevalonate kinase inhibitor, a mevalonate-5-pyrophosphate decarboxylase inhibitor, an isopentenyl pyrophosphate isomerase inhibitor, a farnesyl pyrophosphate synthase inhibitor, a geranylgeranyl pyrophosphate synthase inhibitor or a geranylgeranyl transferase (I, II) inhibitor. Also disclosed is an immunogenic composition comprising inhibitors of mevalonate pathway as an adjuvant.

BENZOXAZINE DERIVATIVES AS GLYCINE TRANSPORT INHIBITORS

The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by Gly T1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: A potent and orally bioavailable NCX inhibitor

Ca2+ overload in myocardial cells is responsible for arrhythmia. Sodium-calcium exchanger (NCX) inhibitors are more effective than sodium-hydrogen exchanger (NHE) inhibitors with regard to modulation of Ca 2+ overload, because NCX inhibitors can directly inhibit the influx of Ca2+ into cells. NCX is an attractive target for the treatment of heart failure and ischemia-reperfusion. We have designed and synthesized a series of N-(2-aminopyridin-4-ylmethyl)nicotinamide derivatives, based on compound 5. We have discovered a novel NCX inhibitor (23h) with an IC 50 value of 0.12 μM against reverse NCX. The inhibitory activities of our NCX inhibitors against cytochrome P450 were also evaluated. The effects on heart failure and the pharmacokinetic profile of compound 23h are discussed.

NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS

The present invention relates to novel compounds (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, A, B, n, X, and Y are as defined in the description and claims; and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament, which acts on the fatty acid binding protein FABP-4. The present invention relates to novel compounds (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, A, B, n, X, and Y are as defined in the description and claims; and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament, which acts on the fatty acid binding protein FABP-4.

Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

The present invention relates to a cyclic urea compound of formula I: as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.

Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa

The discovery of a series of non-peptide factor Xa (FXa) inhibitors incorporating 3-(s)-amino-2-pyrrolidinone as a central template is described. After identifying compound 4, improvements in in vitro potency involved modifications of the liphophilic group and optimizing the angle of presentation of the amidine group to the S1 pocket of FXa. These studies ultimately led to compound RPR120844, a potent inhibitor of FXa (K1 = 7 nM) which shows selectivity for FXa over trypsin, thrombin, and several fibrinolytic serine proteinases. RPR120844 is an effective anticoagulant in both the rat model of FeCl2-induced carotid artery thrombosis and the rabbit model of jugular vein thrombus formation.